Company Description
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.
NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Anil R. Diwan Ph.D. |
Contact Details
Address: 1 Controls Drive Shelton, Connecticut 06484 United States | |
| Phone | (203) 937-6137 |
| Website | nanoviricides.com |
Stock Details
| Ticker Symbol | NNVC |
| Exchange | NYSEAMERICAN |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001379006 |
| CUSIP Number | 630087302 |
| ISIN Number | US6300873022 |
| Employer ID | 76-0674577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anil R. Diwan Ph.D. | Executive Chairman, President, Chief Executive Officer and Secretary |
| Meeta R. Vyas B.S., M.B.A., SB, MBA | Chief Financial Officer |
| Dr. Randall W. Barton Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 424B5 | Filing |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Jan 19, 2024 | 8-K | Current Report |
| Dec 4, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 7, 2023 | 8-K | Current Report |
| Oct 13, 2023 | 10-K | Annual Report |
| Sep 28, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |